Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Up 11.0% in March

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) saw a large increase in short interest in March. As of March 31st, there was short interest totalling 62,800 shares, an increase of 11.0% from the March 15th total of 56,600 shares. Approximately 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 76,600 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Investors Weigh In On Hepion Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new stake in shares of Hepion Pharmaceuticals in the 3rd quarter valued at $1,984,000. BlackRock Inc. raised its holdings in shares of Hepion Pharmaceuticals by 0.3% in the 1st quarter. BlackRock Inc. now owns 1,602,772 shares of the company’s stock valued at $1,245,000 after purchasing an additional 5,206 shares in the last quarter. State Street Corp raised its holdings in shares of Hepion Pharmaceuticals by 8.1% in the 1st quarter. State Street Corp now owns 348,910 shares of the company’s stock valued at $450,000 after purchasing an additional 26,194 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Hepion Pharmaceuticals by 15.8% in the 1st quarter. Renaissance Technologies LLC now owns 284,300 shares of the company’s stock valued at $221,000 after purchasing an additional 38,700 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Hepion Pharmaceuticals by 131.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 202,978 shares of the company’s stock valued at $61,000 after purchasing an additional 115,437 shares in the last quarter. 17.24% of the stock is currently owned by institutional investors and hedge funds.

Hepion Pharmaceuticals Price Performance

Hepion Pharmaceuticals stock traded down $0.14 during mid-day trading on Tuesday, reaching $2.04. 25,712 shares of the company’s stock were exchanged, compared to its average volume of 71,799. Hepion Pharmaceuticals has a twelve month low of $1.49 and a twelve month high of $20.66. The company has a fifty day moving average of $2.31 and a 200-day moving average of $3.01.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.